News

TRON enters into a research collaboration with Astellas Pharma Inc., Japan

Mainz – TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg-University Mainz), a non-profit organization and internationally recognized leader in tumor immunology and cancer therapy research, has entered into a research collaboration with Astellas Pharma Inc., a company dedicated to improving the health of people through the provision of innovative and reliable
Read More

OVERCOMING THE INNATE RESISTANCE OF CANCER TO THERAPY

Trento, Italy, June 26, 2018 – Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small
Read More

Krebstherapien maßgeschneidert für jeden Patienten

Mainz, 17. Mai 2018 – Jeder Tumor ist anders. “Krebs entsteht durch individuelle Mutationen”, erklärt Prof. Dr. Ugur Sahin. “Wenn wir uns zum Beispiel den Lungenkrebs verschiedener Patienten anschauen, dann sind diese sehr unterschiedlich. Sie haben im Durchschnitt weniger als fünf Prozent der Mutationen gemeinsam, 95 Prozent sind ganz individuell. Herkömmliche Therapieansätze konzentrieren sich auf
Read More

Biomedical Informatics Symposium

Mainz, June 20, 2018 – Computational Analysis becomes ever more important for the advancement of personalized medicine. Bioinformatics accelerate the patient-centric molecular characterization of diseases and lead to a deeper understanding of the underlying mechanisms thus facilitating the development of novel drugs. Progress in Artificial Intelligence has a strong impact on clinical decision making in
Read More

The Evolution of RNA-based Cancer Vaccines

Ghent, Belgium, May 25, 2018 – VIB conference series hosts the MEDICAL BIOTECHNOLOGY focus meeting May 24-25, 2018, in Ghent Belgium. The conference features talks on new disruptive technologies for early diagnosis and more effective therapeutic intervention in established chronic diseases. Dr. Mustafa Diken will share years of experience in his talk “The evolution of
Read More

CIMT 2018 Annual Meeting

Mainz, May 15-17, 2018 – CIMT 2018 Annual Meeting We are excited about the upcoming Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in our hometown Mainz. Our scientists will be presenting their research in several sessions and look forward to discussing their projects. Thursday, 17 May 2018, Short Talk Session IV Therapeutic Vaccination
Read More

Prof. Ugur Sahin receives prestigious European Research Council (ERC) Advanced Grant for personalized cancer vaccines

Mainz, Germany, April 18, 2018 – Ugur Sahin, Scientific Director at TRON, has been awarded one of the prestigious ERC Advanced Grants 2017 for his project ‘SUMMIT – Stepping Up mRNA Mutanome Immunotherapy’, totaling 2.5 Million Euros over 5 years. The ERC Advanced Grants are awarded to well-established, leading principal investigators to pursue ground-breaking projects. SUMMIT is one
Read More

Authors Comment: HLA and Proteasome Expression Map

Insight into the human HLA expression pattern opens up new ways of improving cancer vaccine development The human leukocyte antigen system (HLA system) is a group of genes that are central to the function of the immune system. These protein complexes can be found either on almost all cells (HLA class I complex) or on
Read More

Ugur Sahin and Özlem Türeci publish a review in Science’s Cancer Immunotherapy special issue

Mainz, March 23, 2018 – TRON is delighted to announce a review authored by Ugur Sahin and Özlem Türeci in the journal Science. “Personalized vaccines for cancer immunotherapy” outlines the genetic basis for why almost every cancer is unique, and how with innovations in mutation mapping, target validation and vaccine production, it is possible to
Read More

TRON Seminars in Translational Oncology: Prof. Dietmar Zehn

Mainz, March 2018 – On March 15th, Prof. Dietmar Zehn from the Technical University of Munich, School of Life Sciences Weihenstephan, will be visiting Mainz in the context of our Seminars in Translational Oncology series (SITO). You are cordially invited to his talk at 5 pm in building 708 of the University Medicine Mainz. The
Read More

Ugur Sahin at Keystone Symposium “Antibodies as Drugs”

Mainz, February 16, 2018 – The Keystone Symposium on Antibodies as Drugs: Translating Molecules into Treatments, will take place February 25th – March 1st, 2018 at the Whistler Conference Centre in Whistler, Canada. Ugur Sahin will speak in the session on Novel Ways to Deliver Antibody Therapy on Thursday, March 1.  The title of his lecture
Read More

Three-year research grant to develop new treatment approaches for neuroendocrine tumors

We are pleased to announce a three-year grant from the Falconwood Foundation, New York, USA, totalling 3 Million Euros. The grant supports the launch of a new research project to identify biomarkers specific for neuroendocrine tumors (NETs) that are crucial for the development of new, personalized immunotherapies to treat NET patients. Further details are announced
Read More

TRON shortlisted for Cancer Research UK’s Grand Challenge Award

TRON has been shortlisted for Cancer Research UK’s Grand  Challenge Award as part of team BLUEPRINT   TRON is part of a multi-disciplinary team of scientists that has been shortlisted to the final stages of Cancer Research UK’s Grand Challenge*. The team is led by Dr. Lindy Durrant from the University of Nottingham and includes
Read More

Ugur Sahin at the Keystone Symposium on Lymphocytes and their Role in Cancer

Mainz, January 23, 2018 – The Keystone Symposium on Lymphocytes and their Role in Cancer will take place February 11th-15th 2018 at the Keystone Resort in Keystone, Colorado.  This is a joint event with Emerging Cellular Therapies: T Cells and Beyond. Ugur Sahin will chair the session on Cellular Therapies in Blood Malignancies,  and give a
Read More

Authors’ comments on article in Human Gene Therapy

The concept of delivering genetic material to defective cells to treat diseases or to vaccinate healthy people against infections has been around for quite some time. Nevertheless, key challenges remain, such as efficient delivery of the material as well as duration of gene expression.
Read More

TRON is involved in two projects of a new Collaborative Research Center

In the course of evolution, the immune system has developed sophisticated mechanisms to identify and eliminate invading pathogens and degenerate cells, thereby preventing infection and tumor occurrence.  When these mechanisms are ineffective or somehow bypassed, tumors or chronic infections may form. Clarifying the processes leading to ineffective immune defense is the central goal of the
Read More

Antibody Engineering and Therapeutics conference

The Antibody Engineering and Therapeutics conference will take place December 11th-15th 2017 at the Manchester Grand Hyatt in San Diego, California.
Read More

Mustafa Diken speaks at Future Medicine 2017.

The Berlin Institute of Health, together with the Charité Universitätsmedizin Berlin, Max Delbrück Center for Molecule Medicine and Tagesspiegel, will host the second Future Medicine: Innovation in Health Science meeting on 7th November.
Read More

Honorary Medical Doctor’s Degree for Cornelis Melief

Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about
Read More

Ruggero Ceppellini Advanced School of Immunology

The topic of this year’s EFIS-EJI Ruggero-Ceppellini Advanced School of Immunology is “Tumour Immunology: from tissue microenvironment to immunotherapy.”
Read More

Neue Krebsimmuntherapien – Ugur Sahin im Expertengespräch

Was versprechen neuartige personalisierte Krebsimmuntherapien? Wie können Patienten von Ihnen profitieren, und welche Risiken bergen die Behandlungen? Zwei neue Ansätze in der Krebsimmuntherapie sind die CAR-T-Methode und die so genannten Neoantigen-Vakzine. Beide werden gerade getestet und sind sehr vielversprechend. Der regionale Radiosender SWR2 sendete hierzu einen Radiobeitrag in seinem Programm. Einen Mitschnitt sowie ein Transkript
Read More

Ugur Sahin at the NCI Cancer Immunology and Immunotherapy Symposium

The National Cancer Institute’s Center of Excellence in Immunogy sponsors a two-day symposium with the theme “Cancer Immunology and Immunotherapy: From Conception to Delivery”.
Read More

Mustafa Diken speaks at Radboud UMC MMD symposium “Chemical Immunology”

The Institute for Molecular Life Sciences at Radboud University Medical Center (RIMLS) will host a mini-symposium entitled “Chemical Immunology”. 
Read More

12th Mainz Clinical Pathology Seminar

The 12th Mainz Clinical Pathology Seminar will assemble experts from the basic scientific, clinical, biopharmaceutical and pathological fields to give an overview of the exciting developments in cancer immunotherapies.
Read More

1st Crick International Cancer Conference

The 1st Crick International Cancer Conference will bring together leading cancer scientists from all over the world to discuss the latest findings in cancer metabolism, the tumor microenvironment, and how the cancer genotype changes over time.
Read More

The Annual Meeting of the Leopoldina National Academy of Sciences

Mainz, September 23, 2017 – The Annual Meeting of the Leopoldina National Academy of Sciences will be held on 22 and 23 September in Halle (Saale).
Read More

27th German Skin Cancer Congress

Mainz, September 21, 2017 – The working group Dermatological Oncology (ADO) organizes from 21-23 September the 27th German Skin Cancer Congress in the Rheingoldhalle Mainz.
Read More

Improvement of in vivo expression of genes delivered by self-amplifying RNA using Vaccinia Virus immune evasion proteins

Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human
Read More

Seminar in Translational Oncology – Prof. Federico Garrido

Mainz, September 2017 – Am 14. September kommt im Rahmen der Seminarreihe in Translational Oncology (SITO) Prof. Federico Garrido der Universität von Granada Medical School nach Mainz. Sie sind herzlich zu seinem Vortrag um 17.00 Uhr c.t. in Gebäude 708 der Universitätsmedizin Mainz eingeladen.
Read More

Individualized cancer immunotherapy

Mainz, September 6, 2017 – Individualized cancer immunotherapy Prof. Ugur Sahin, Managing Director (Science and Research) and Co-Founder of TRON, will talk at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in our hometown Mainz. His talk is titled “Individualized Cancer Immunotherapy – Exploring a new landscape” and will cover the implementation of an RNA-based approach
Read More